share_log

Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $231

Benzinga ·  Nov 3, 2023 10:51

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $269 to $231.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment